The present invention relates to synthetic α-secretase (SAS) and a use thereof. According to the present invention, a synthetic α-secretase, which is a fusion protein comprising, as an active ingredient, NIa protease, a fragment thereof or a variant thereof, can inhibit the formation of amyloid β, degrade extracellularly secreted amyloid β, and degrade amyloid β internalized in cells. Therefore, the present invention allows intracellular/extracellular degradation of amyloid β, which is the cause of various diseases including Alzheimer's disease, and thus can be usable in the prevention or treatment of such diseases.

The present invention provides compositions comprising cellular receptor mimics and methods for treating or preventing coronavirus infection or a disease or disorder associated with coronavirus infection such as COVID-19.

Disclosed herein are kits and methods for quantifying the amount of collagen in a test sample. The kits and methods described involve the use of undenatured type II collagen as a standard for producing accurate and reproducible results with respect to quantifying the amount of collagen in a sample used in cosmetics, food products, and pharmaceuticals or nutritional supplements.

The present invention relates to mammalian cells modified to provide for improved expression of a recombinant protein of interest. In particular, the invention relates to CHO cells and other host cells in which the expression of one or more endogenous secreted proteins has been disrupted, as well as to the preparation, identification and use of such cells in the production of recombinant proteins.

The present invention relates to mammalian cells modified to provide for improved expression of a recombinant protein of interest. In particular, the invention relates to CHO cells and other host cells in which the expression of one or more endogenous secreted proteins has been disrupted, as well as to the preparation, identification and use of such cells in the production of recombinant proteins.

A method of decellularizing in an animal tissue includes digesting the animal tissue; treating the animal tissue with a surfactant: treating the animal tissue with at least one zwitterionic detergent to form a decellularized animal tissue; and treating the decellularized animal tissue with at least one advanced glycation end-product (AGE) inhibitor to reduce AGE crosslinking in the decellularized animal tissue. The decellularized animal tissue may be ground into a powder and dissolved in a digest solution to form a bioink composition useful for 3D printing an in vitro model of healthy or diseased tissue.

The transgenic plants engineered to express animal-derived proteins, such as myoglobin, casein, chymosin, hemoglobin and actin and other animal-derived proteins, and the nucleic acids encoding the same are described herein. Methods of making and identifying the transgenic plants, processing the seeds from the transgenic plants that contain the expressed animal-derived proteins, isolating and purifying the expressed proteins, and utilizing the expressed proteins in food are provided. Food and food ingredients that include myoglobin, casein, chymosin, hemoglobin and actin are also disclosed herein. Genes encoding myoglobin, casein, hemoglobin and actin forms that have been modified to improve performance as components of food are described.